---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-070007"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2022-03-09T23:59:59+00:00"
generated_at: "2026-06-27T00:26:45.702556+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Prelude appoints Jane Huang as President & CMO; updates pipeline prioritizing PRT811 and IV PRT1419

## Summary
- Appoints Jane Huang President & CMO effective April 4, 2022; compensation: $525k base, 50% bonus target, 150k RSUs, 460k options.
- Prioritizes PRT811 over PRT543 for PRMT5 program due to superior safety & brain penetration; expansion cohort data in 2H2022.
- New pipeline candidate PRT3645, a highly brain-penetrant CDK4/6 inhibitor; IND submission planned mid-2022.
- IV formulation of MCL1 inhibitor PRT1419 prioritized; combination trial with venetoclax starts mid-2022; RP2D by 2H2022.
- SMARCA2/BRM degrader progress; IND submission planned by year-end 2022.

## SEC filing metadata
- accession: 0001193125-22-070007
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2022-03-09T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312522070007/0001193125-22-070007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312522070007/d641589d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-070007
- JSON: https://secwatch.observer/filing/0001193125-22-070007.json
- Plain text: https://secwatch.observer/filing/0001193125-22-070007.txt

## Key facts
- Executive change
  Jane Huang was appointed as President and Chief Medical Officer at Prelude Therapeutics Inc.
  - Action: appointed
  - Role: President and Chief Medical Officer
  source text: the Board of Directors of the Company (the “ Board ”) appointed Jane Huang, M.D., age 49, as the President and Chief Medical Officer of the Company, effective on or about April 4, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000119312522070007/0001193125-22-070007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.